Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos, Idenix Pen Hepatitis and HIV Drug-Discovery Pact

NEW YORK, Nov. 28 (GenomeWeb News) - Galapagos NV and Idenix Pharmaceuticals will collaborate on hepatitis and HIV infectious disease programs, Galapagos said last week.

 

Under the agreement, which is worth up to $2.5 million over two years, BioFocus, Galapagos' service division, will supply Idenix with its SoftFocus chemical compound collections. BioFocus will provide hit-to-lead and lead-optimization services.

 

Galapagos will receive technology access fees for SoftFocus, fee components for medicinal chemistry services, and success payments after identifying pre-clinical candidates. The amounts were not specified.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.